Actively Recruiting
Phase 1 Trial of Intratumoral CP-IL22BP mRNA Gene Therapy to Evaluate Safety and Preliminary Antitumor Activity in Adults With Advanced Solid Tumors
Led by West China Hospital · Updated on 2026-07-14
18
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a peptide-delivered IL-22BP mRNA gene therapy in adults with advanced solid tumors that have not responded to standard treatments. This phase 1 trial aims to assess the safety, tolerability, and early antitumor effects of this new gene therapy. The investigational product uses a natural amino acid-based peptide delivery system designed to improve safety and avoid limitations of conventional methods. Participants will receive the investigational CP-IL22BP mRNA through intratumoral injections. Five doses will be administered, with the first dose followed by weekly injections. The study uses a dose-escalation design with three fixed dose levels to identify safe and tolerable dosing. This is a single-group, open-label trial without randomization. During the study, participants will be closely monitored for adverse effects and treatment discontinuation up to 9 weeks after the first dose. Researchers will also assess tumor response and survival outcomes for up to 6 to 12 months. Various laboratory tests, imaging, and clinical evaluations will be performed to track safety, tolerability, and preliminary antitumor activity throughout the trial.
CONDITIONS
Brief Title
Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors
Research Team
X
Xingchen PXC Peng, Ph.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here